Compare Devon Energy Corp (DVN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Incyte Corporation — how do they compare? Devon Energy Corp trades at $48.26 (market cap $53.81B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Devon Energy Corp is far larger — about 2.4× Incyte Corporation's market cap, and Devon Energy Corp pays a 2.62% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Incyte Corporation for 33 Days on average.
| DVN | INCY | |
|---|---|---|
Market Cap | $53.81B | $22.85B |
Volume | 11,556,740 | 1,927,029 |
Sector | Energy | Health |
52-Week High | $52.07 | $129.93 |
52-Week Low | $31.74 | $83.80 |
Typical Hold Time | 136 Days | 33 Days |
Enterprise Value | $64.55B | $18.35B |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.92, up 2.17% today, with strong analyst support showing 72% buy ratings and a $62.53 consensus price target. The stock shows bullish technical momentum above key support levels, while fundamentals reveal solid profitability with 16.67% net margins and attractive valuation at 10.63 P/E. Recent activist pressure from Toms Capital for strategic alternatives and potential asset sales with BP creates near-term catalysts.
DVN presents compelling value with upside potential to analyst targets, though faces execution risks on asset sales and oil price volatility. The company's improving cash flow generation and Permian Basin focus support the bullish case, but investors should monitor activist developments and energy market conditions closely.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
